



Contents

- News and Commentary
- Media Releases
- Latest Research
- The Industry
- Leading Companies in the Industry

This Week's News

Business News Australia - Cancer-fighting biotech ImmVirX secures \$15m from OneVentures - 6/6/2023

ImmVirX aims to raise the remaining \$10 million from a combination of existing shareholders and new investors, with players like Acorn Capital having already placed a bid to participate. For the complete story, see:

<https://www.businessnewsaustralia.com/articles/cancer-fighting-biotech-immvirx-secures--15m-from-oneventures.html>

The National Tribune - University of Enterprise on mission to expand biotech partnerships - 6/6/2023

UniSA is the only university participating in the 16-organisation delegation led by the South Australian Government.

For the complete story, see:

<https://www.nationaltribune.com.au/university-of-enterprise-on-mission-to-expand-biotech-partnerships/>

Australian Manufacturing - Queensland's biotech industry to take centre stage at BIO Convention - 6/6/2023

Queensland universities, research institutions, and leading businesses in the biomedical industry are set to showcase their innovations at the largest biotechnology conference in the world.

For the complete story, see:

<https://www.australianmanufacturing.com.au/queenslands-biotech-industry-to-take-centre-stage-at-bio-convention/>

Other Stories

Australian Manufacturing - Sigma inks Chemist Warehouse supply contract for PBS, FMCG goods - 6/6/2023

Proactive Investors - Recce Pharmaceuticals recruits outpatient nurses to drive "largest in Australia" diabetic foot infection clinical trial - 28/5/2023

Mirage News - Pharmaxis Trial Shows Positive Results for PXS-6302 - 25/5/2023

Ragtrader - Nanollose secures \$300k tax rebate for fibre research - 23/5/2023

BioSpectrum Asia - Australian pharma firm Amplia partners with CSIRO to develop wound healing solutions - 23/5/2023

Media Releases

CSL Limited (ASX: CSL) - Injectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure - 5/6/2023

Immutep Limited (ASX: IMM, NASDAQ: IMMP) - Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting - 5/6/2023

Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) - VIRALEZE™ Nasal Spray Approved in Malaysia (ASX Announcement) - 5/6/2023

Immutep Limited (ASX: IMM, NASDAQ: IMMP) - Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer - 2/6/2023

Latest Research

Dual use research of concern in the pharmaceutical industry: A Comparative Analysis of the Ethical Guidelines and Codes of Conduct for Researchers - By Anamika Chatterjee, KU Leuven

Industry Overview

The Biotechnology Industry

Overviews of Leading Companies

Acrux Limited (ASX: ACR)

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE)

Industry SnapShotsPublished by **Acquisdata Pty Ltd**

A.C.N. 147 825 536

ISSN 2203-2738 (Electronic)

©Acquisdata Pty Ltd 2023

www.acquisdata.com**Disclaimer of Warranties and Liability**

Due to the number of sources from which the information and services on the Acquisdata Pty Ltd Service are obtained, and the inherent hazards of electronic distribution, there may be delays, omissions or inaccuracies in such information and services. Acquisdata Pty Ltd and its affiliates, agents, sales representatives, distributors, and licensors cannot and do not warrant the accuracy, completeness, currentness, merchant ability or fitness for a particular purpose of the information or services available through the Acquisdata Pty Ltd service. In no event will Acquisdata Pty Ltd, its affiliates, agents, sales representatives, distributors or licensors be liable to licensee or anyone else for any loss or injury caused in whole or part by contingencies beyond its control in procuring, compiling, interpreting, editing, writing, reporting or delivering any information or services through the Acquisdata Pty Ltd Service. In no event will Acquisdata Pty Ltd or its affiliates, agents, sales representatives, distributors or licensors be liable to licensee or anyone else for any decision made or action taken by licensee in reliance upon such information or services or for any consequential, special or similar damages, even if advised of the possibility of such damages. licensee agrees that the liability of Acquisdata Pty Ltd, its affiliates, agents, sales representatives, distributors and licensors, if any, arising out of any kind of legal claim (whether in contract, tort or otherwise) in any way connected with the Acquisdata Pty Ltd service shall not exceed the amount licensee paid for the use of the Acquisdata Pty Ltd service in the twelve (12) months immediately preceding the event giving rise to such claim.

Benitec Biopharma Limited (ASX: BLT)
Bionomics Limited (ASX: BNO, OTCQX: BNOEF)
Clinuvel Pharmaceuticals Limited (ASX: CUV)
CSL Limited (ASX: CSL)
Genera Biosystems Limited
Hygrovest Limited (ASX: HGV)
IDT Australia Limited (ASX: IDT)
Immutep Limited (ASX: IMM, NASDAQ: IMMP)
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA)
Mayne Pharma Group Limited (ASX: MYX)
Medical Developments International Limited (ASX: MVP)
Medlab Clinical Limited (ASX: MDC)
Mesoblast Limited (ASX: MSB; NASDAQ: MESO)
Monash IVF Group (ASX: MVF)
Neuren Pharmaceuticals Limited (ASX: NEU)
Palla Pharma Limited (ASX: PAL)
Pharmaxis Limited (ASX: PXS)
PolyNovo Limited (ASX: PNV)
Sirtex Medical Limited
Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY)
Viralytics Limited (NYSE: MRK)
Vita Life Sciences Limited (ASX: VLS)

Senior Associate: Joseph Hang Ellison